Deppa v. Abbott Laboratories, Inc.

Constitutional Issues

Whether state-law consumer protection claims are preempted by federal law governing the marketing of infant formula.

Rule Statements

State law claims are preempted by federal law when they 'stand as an obstacle to the accomplishment and execution of the full purposes and objectives of Congress.'

The court must determine whether the plaintiff's claims under the Illinois Consumer Fraud and Deceptive Practices Act are preempted by the Federal Food, Drug, and Cosmetic Act and its implementing regulations.

Q: What is Deppa v. Abbott Laboratories, Inc. about?

Deppa v. Abbott Laboratories, Inc. is a case decided by Illinois Appellate Court on December 12, 2025.

Q: What court decided Deppa v. Abbott Laboratories, Inc.?

Deppa v. Abbott Laboratories, Inc. was decided by the Illinois Appellate Court, which is part of the IL state court system. This is a state appellate court.

Q: When was Deppa v. Abbott Laboratories, Inc. decided?

Deppa v. Abbott Laboratories, Inc. was decided on December 12, 2025.

Q: What is the citation for Deppa v. Abbott Laboratories, Inc.?

The citation for Deppa v. Abbott Laboratories, Inc. is 2025 IL App (1st) 241795. Use this citation to reference the case in legal documents and research.

Q: What is the case of Deppa v. Abbott Laboratories about?

Deppa v. Abbott Laboratories, Inc. involves a lawsuit filed by a plaintiff named Deppa against Abbott Laboratories. Deppa alleged that Abbott's cow's milk-based infant formula caused her child to develop necrotizing enterocolitis (NEC) and that Abbott failed to provide adequate warnings about this risk. The case ultimately centered on whether federal law preempted these state-law claims.

Q: Who were the parties involved in Deppa v. Abbott Laboratories?

The primary parties in Deppa v. Abbott Laboratories were the plaintiff, Deppa, who brought the lawsuit on behalf of her child, and the defendant, Abbott Laboratories, the manufacturer of the infant formula in question.

Q: Which court decided Deppa v. Abbott Laboratories?

The appellate court, specifically the Illinois Appellate Court, decided the case of Deppa v. Abbott Laboratories, Inc. This decision affirmed the trial court's earlier ruling.

Q: When was the Deppa v. Abbott Laboratories decision issued?

The Illinois Appellate Court issued its decision in Deppa v. Abbott Laboratories, Inc. on December 15, 2023. This date marks the affirmation of the trial court's dismissal.

Q: What is necrotizing enterocolitis (NEC) and how did it relate to the lawsuit?

Necrotizing enterocolitis (NEC) is a serious intestinal disease that can affect premature infants. The plaintiff, Deppa, alleged that Abbott Laboratories' cow's milk-based infant formula caused her child to develop NEC, forming the basis of her product liability claims.

Q: Is Deppa v. Abbott Laboratories, Inc. published?

Deppa v. Abbott Laboratories, Inc. is a published, precedential opinion. Published opinions carry precedential weight and can be cited as authority in future cases.

Q: What was the ruling in Deppa v. Abbott Laboratories, Inc.?

The court ruled in favor of the defendant in Deppa v. Abbott Laboratories, Inc.. Key holdings: The court held that the plaintiff's state-law claims for failure to warn regarding the risk of necrotizing enterocolitis (NEC) from cow's milk-based infant formula were preempted by federal law.; The court reasoned that the Food, Drug, and Cosmetic Act (FDCA) and its implementing regulations establish a comprehensive federal scheme for the labeling of infant formula, including specific requirements for nutritional content and warnings.; The court found that allowing state-law failure-to-warn claims would impose different or additional labeling requirements than those mandated by federal law, thus falling under the express preemption provision of the FDCA.; The court concluded that the plaintiff could not circumvent federal preemption by framing her claims as common-law negligence or strict liability, as these claims still sought to impose labeling requirements beyond those set by federal regulations.; The court affirmed the trial court's dismissal of the case, finding that the plaintiff failed to state a claim upon which relief could be granted due to federal preemption..

Q: Why is Deppa v. Abbott Laboratories, Inc. important?

Deppa v. Abbott Laboratories, Inc. has an impact score of 75/100, indicating significant legal impact. This decision reinforces the broad preemptive power of federal regulations, particularly the FDCA, over state-law product liability claims concerning infant formula labeling. Manufacturers of FDA-regulated products should be aware that state-law claims attempting to impose different or additional labeling requirements may be dismissed on preemption grounds, potentially limiting consumer recourse.

Q: What precedent does Deppa v. Abbott Laboratories, Inc. set?

Deppa v. Abbott Laboratories, Inc. established the following key holdings: (1) The court held that the plaintiff's state-law claims for failure to warn regarding the risk of necrotizing enterocolitis (NEC) from cow's milk-based infant formula were preempted by federal law. (2) The court reasoned that the Food, Drug, and Cosmetic Act (FDCA) and its implementing regulations establish a comprehensive federal scheme for the labeling of infant formula, including specific requirements for nutritional content and warnings. (3) The court found that allowing state-law failure-to-warn claims would impose different or additional labeling requirements than those mandated by federal law, thus falling under the express preemption provision of the FDCA. (4) The court concluded that the plaintiff could not circumvent federal preemption by framing her claims as common-law negligence or strict liability, as these claims still sought to impose labeling requirements beyond those set by federal regulations. (5) The court affirmed the trial court's dismissal of the case, finding that the plaintiff failed to state a claim upon which relief could be granted due to federal preemption.

Q: What are the key holdings in Deppa v. Abbott Laboratories, Inc.?

1. The court held that the plaintiff's state-law claims for failure to warn regarding the risk of necrotizing enterocolitis (NEC) from cow's milk-based infant formula were preempted by federal law. 2. The court reasoned that the Food, Drug, and Cosmetic Act (FDCA) and its implementing regulations establish a comprehensive federal scheme for the labeling of infant formula, including specific requirements for nutritional content and warnings. 3. The court found that allowing state-law failure-to-warn claims would impose different or additional labeling requirements than those mandated by federal law, thus falling under the express preemption provision of the FDCA. 4. The court concluded that the plaintiff could not circumvent federal preemption by framing her claims as common-law negligence or strict liability, as these claims still sought to impose labeling requirements beyond those set by federal regulations. 5. The court affirmed the trial court's dismissal of the case, finding that the plaintiff failed to state a claim upon which relief could be granted due to federal preemption.

Q: What cases are related to Deppa v. Abbott Laboratories, Inc.?

Precedent cases cited or related to Deppa v. Abbott Laboratories, Inc.: 21 U.S.C. § 343(g); 21 C.F.R. § 107.10; 21 C.F.R. § 107.20.

Q: What was the core legal issue in Deppa v. Abbott Laboratories?

The core legal issue in Deppa v. Abbott Laboratories was whether the plaintiff's state-law claims, alleging Abbott failed to adequately warn about the risks of its infant formula causing NEC, were preempted by federal law, specifically the Food, Drug, and Cosmetic Act (FDCA).

Q: What federal law was central to the preemption argument in Deppa v. Abbott Laboratories?

The federal law central to the preemption argument in Deppa v. Abbott Laboratories was the Food, Drug, and Cosmetic Act (FDCA). The court focused on the FDCA's requirements for infant formula labeling and its provisions that preempt state laws imposing different or additional labeling requirements.

Q: What was the plaintiff's main argument against Abbott Laboratories?

The plaintiff, Deppa, argued that Abbott Laboratories failed to adequately warn consumers about the risks that its cow's milk-based infant formula could cause necrotizing enterocolitis (NEC) in infants. This failure to warn formed the basis of her product liability claims.

Q: What does it mean for a claim to be 'preempted' by federal law?

Preemption means that a federal law overrides or supersedes state law. In Deppa v. Abbott Laboratories, the court determined that the FDCA's specific labeling requirements for infant formula prevented the plaintiff from pursuing state-law claims that would impose different or additional warning obligations on the manufacturer.

Q: How did the court interpret the labeling requirements of the Food, Drug, and Cosmetic Act (FDCA)?

The court interpreted the FDCA's labeling requirements for infant formula as comprehensive and specific. It found that these federal regulations preempted state-law claims that sought to impose different or additional labeling requirements, such as the plaintiff's failure-to-warn claim.

Q: Did the court consider the specific scientific evidence linking infant formula to NEC?

While the plaintiff alleged a link between the formula and NEC, the court's decision focused on the legal issue of federal preemption. The court did not delve deeply into the scientific evidence of causation because it found the claims were barred by federal law before reaching the merits of the scientific dispute.

Q: What would have been required for Deppa's claims to proceed?

For Deppa's claims to proceed, she would have needed to demonstrate that her state-law failure-to-warn claims were not preempted by the FDCA. This would likely involve arguing that her claims did not seek to impose different or additional labeling requirements than those already mandated by federal law.

Q: What is the significance of the FDCA's preemption provision in cases like this?

The FDCA's preemption provision is significant because it aims to create a uniform national standard for infant formula labeling. This prevents manufacturers from having to comply with a patchwork of different state labeling laws, but it also limits the ability of states to provide additional protections through tort law.

Q: Does the Deppa v. Abbott Laboratories ruling mean infant formula is safe?

The ruling in Deppa v. Abbott Laboratories does not make a determination on the safety of infant formula. Instead, it decided that the plaintiff's specific legal claims were barred by federal preemption, meaning the court did not rule on the merits of whether the formula caused harm or if warnings were inadequate under state law.

Q: What is the burden of proof in a preemption case like this?

In preemption cases, the party seeking to benefit from federal law (here, Abbott Laboratories) typically bears the burden of proving that federal law preempts the state-law claims. The court then analyzes whether the specific state claims conflict with the federal regulatory scheme.

Q: What specific federal labeling requirements were at issue?

The specific federal labeling requirements at issue stemmed from the FDCA and its implementing regulations for infant formula. These regulations dictate the content and format of labeling, and the court found that Deppa's claims would impose different or additional requirements, thus triggering preemption.

Q: How does Deppa v. Abbott Laboratories, Inc. affect me?

This decision reinforces the broad preemptive power of federal regulations, particularly the FDCA, over state-law product liability claims concerning infant formula labeling. Manufacturers of FDA-regulated products should be aware that state-law claims attempting to impose different or additional labeling requirements may be dismissed on preemption grounds, potentially limiting consumer recourse. As a decision from a state appellate court, its reach is limited to the state jurisdiction. This case is moderate in legal complexity to understand.

Q: What is the practical impact of the Deppa v. Abbott Laboratories decision on consumers?

For consumers, the decision means that lawsuits based on state-law failure-to-warn claims regarding infant formula labeling may be difficult to pursue if they conflict with federal regulations. It reinforces that federal law dictates the specific warnings required for such products.

Q: What are the implications for future lawsuits alleging harm from infant formula?

Future lawsuits alleging harm from infant formula, particularly those based on failure-to-warn claims, will likely face the same preemption challenge seen in Deppa v. Abbott Laboratories. Plaintiffs will need to carefully craft their claims to avoid direct conflict with federal labeling regulations.

Q: How does this case fit into the broader legal landscape of product liability and federal preemption?

Deppa v. Abbott Laboratories fits into a long line of cases where manufacturers argue that federal regulations, particularly in areas like pharmaceuticals and food, preempt state-law tort claims. The decision highlights the significant hurdle plaintiffs face when their claims challenge federally regulated labeling.

Q: Are there other cases similar to Deppa v. Abbott Laboratories regarding infant formula and NEC?

Yes, there have been other lawsuits filed against infant formula manufacturers concerning allegations that their products cause NEC. These cases often involve similar legal battles over federal preemption, making Deppa v. Abbott Laboratories part of an ongoing legal discussion.

Q: What was the docket number in Deppa v. Abbott Laboratories, Inc.?

The docket number for Deppa v. Abbott Laboratories, Inc. is 1-24-1795. This identifier is used to track the case through the court system.

Q: Can Deppa v. Abbott Laboratories, Inc. be appealed?

Yes — decisions from state appellate courts can typically be appealed to the state supreme court, though review is often discretionary.

Q: What was the outcome of the Deppa v. Abbott Laboratories case?

The appellate court affirmed the trial court's dismissal of the case. The court found that Deppa's claims were preempted by federal law, meaning her state-law claims could not proceed because they conflicted with federal labeling requirements for infant formula.

Q: What was the procedural posture of the case when it reached the appellate court?

The case reached the appellate court after the trial court had dismissed Deppa's claims. The appellate court's role was to review the trial court's decision to ensure it was legally correct, which in this instance, it affirmed.

Q: Could Deppa have pursued her claims in federal court instead of state court?

While the opinion doesn't explicitly state why the case was in state court, product liability claims can often be brought in either state or federal court depending on factors like diversity of citizenship. However, the preemption issue would likely be a significant hurdle regardless of the forum.

Q: Could this decision be appealed to a higher court, like the Illinois Supreme Court?

Yes, depending on the specific rules and procedures of the Illinois court system, the plaintiff may have grounds to seek further review from a higher court, such as the Illinois Supreme Court. The appellate court's decision is not necessarily the final word on the matter.